SerpApi.Org
Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside pembrolizumab continue to show fewer recurrences than those treated with pembrolizumab alone, now five years into the KEYNOTE-942 trial. The randomized, phase 2b study, which enrolled participants between 2019 and 2021, tested whether the individualized neoantigen therapy mRNA-4157, also known as V940, could extend recurrence-free survival after surgical removal of stage III or IV melanoma. The durability of the benefit is the central question as the trial matures, because checkpoint inhibitors given after surgery often lose their protective edge over time.
Why the KEYNOTE-942 vaccine trial matters right now
Standard adjuvant therapy for resected melanoma relies on checkpoint inhibitors such as pembrolizumab. These drugs can delay or prevent recurrence, but a meaningful share of patients still see their cancer return within a few years. The KEYNOTE-942 trial was designed to test whether adding a personalized vaccine, built from mRNA encoding up to 34 patient-specific tumor mutations, could widen the gap between treated and untreated disease.
The hypothesis driving the trial is straightforward: a vaccine that teaches the immune system to recognize the unique fingerprint of a patient’s own tumor should generate neoantigen-specific T cells capable of hunting down residual cancer cells that surgery missed. If those T cells persist in the body and re-expand when they encounter traces of disease, the benefit should grow more durable over time rather than fade. That pattern would look different from the gradual convergence of survival curves often seen with checkpoint inhibitors alone. The five-year mark is a critical window for distinguishing a lasting immune memory effect from a temporary boost.
The KEYNOTE-942 listing confirms the study’s formal title: An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma. Moderna and Merck are the sponsors. Patients were randomly assigned to receive either the combination or pembrolizumab monotherapy, making this one of the first controlled tests of a personalized cancer vaccine in a post-surgical setting.
Published efficacy data from the phase 2b melanoma study
Results from the trial were published in The Lancet as a phase 2b analysis reporting on recurrence-free survival and distant metastasis-free survival. The publication established the initial efficacy signal: the combination of mRNA-4157 (V940) plus pembrolizumab reduced the risk of recurrence or death compared with pembrolizumab alone over the reported follow-up period. While the exact numerical outcomes are detailed in that paper, the overarching conclusion was that personalized vaccination added to checkpoint blockade produced a clinically meaningful reduction in relapse risk.
The vaccine itself is manufactured individually for each patient. After tumor tissue is sequenced, algorithms identify the mutations most likely to provoke an immune response. Those mutations are encoded into a single mRNA molecule, which is then injected to train the patient’s T cells. The approach borrows the mRNA delivery platform Moderna developed for infectious disease vaccines but applies it to cancer-specific targets. Each dose is unique, a feature that separates this strategy from older “shared antigen” vaccines that targeted proteins common across many tumors but rarely produced strong clinical results.
The trial’s design as a randomized study with a monotherapy control arm gives the data more weight than single-arm studies that lack a direct comparison. Because every participant received pembrolizumab, any separation in outcomes can be attributed to the vaccine component rather than to differences in background therapy. The corresponding registry record lists recurrence-free survival as the primary endpoint, with distant metastasis-free survival and overall survival tracked as secondary measures. Safety, including immune-related adverse events, is also monitored, an important consideration when combining an immune-activating vaccine with a checkpoint inhibitor.
In the published analysis, the investigators reported that the addition of mRNA-4157 did not introduce unexpected safety signals compared with pembrolizumab alone. Most side effects were consistent with those seen with checkpoint blockade, along with transient, vaccine-related reactions such as injection-site discomfort and flu-like symptoms. This tolerability profile is central to the rationale for moving forward into larger, confirmatory trials, because adjuvant therapies are given to patients who may already be free of detectable disease after surgery.
Open questions as KEYNOTE-942 reaches five years
The strongest limitation at this stage is the absence of fully detailed five-year endpoint data in the public domain. The Lancet publication reported earlier follow-up results, and no updated hazard ratios, Kaplan-Meier curves, or patient-level counts at the five-year mark have appeared in the primary registry or its linked publications as of mid-2019. The latest publicly available update described in the literature covers a shorter observation period. Without those numbers, the claim that the vaccine is still holding melanoma at bay rests on the trajectory established in earlier readouts rather than on a confirmed five-year dataset.
Several scientific questions remain open. First, researchers have not yet demonstrated in published data from this trial whether neoantigen-specific T cells generated by mRNA-4157 persist at detectable levels years after vaccination. If the survival curves continue to separate with longer follow-up, that would be indirect evidence of durable immune memory. If the curves converge, it would suggest the vaccine provided a temporary acceleration of immune response rather than a lasting shift in the tumor–immune equilibrium.
Second, the trial enrolled a relatively modest number of patients for a phase 2b study, which limits the statistical power to detect differences in overall survival, an endpoint that typically requires longer follow-up and larger populations. While recurrence-free survival is an accepted surrogate in melanoma adjuvant trials, regulators and clinicians will want to see whether the early reduction in relapse risk ultimately translates into fewer deaths from melanoma.
Third, generalizability remains uncertain. KEYNOTE-942 focuses on patients with resected stage III and IV melanoma who are fit enough to receive pembrolizumab and undergo a bespoke manufacturing process. It is not yet clear how well this approach would perform in patients with earlier-stage disease, in those with significant comorbidities, or in health systems that lack the infrastructure to support individualized vaccine production on tight timelines.
The path from phase 2b to regulatory decisions
Moving from a positive phase 2b signal to a therapy that changes standard practice will require several steps. A larger, phase 3 trial powered for overall survival and designed with regulatory input is the logical next move. Such a study would need to confirm the magnitude and durability of benefit, further characterize safety, and test whether the vaccine adds value across diverse subgroups, including different mutational profiles and levels of tumor-infiltrating lymphocytes.
Regulators will also weigh practical considerations. Personalized mRNA vaccines depend on rapid sequencing, computational epitope prediction, and just-in-time manufacturing. Demonstrating that this workflow can be delivered reliably and at scale, without excessive delays between surgery and the first vaccine dose, will be as important as the clinical data. Health systems will have to decide whether the anticipated reduction in recurrences justifies the complexity and cost of individualized production.
For now, the KEYNOTE-942 experience offers a proof-of-concept that personalized neoantigen vaccines can be integrated with checkpoint inhibitors in the adjuvant setting and can produce encouraging early outcomes. As five-year data mature and additional trials open in other tumor types, the field will gain a clearer picture of whether this strategy can deliver the durable, long-term control that patients and clinicians are hoping for, or whether its benefits will prove more time-limited. Until then, the trial stands as a closely watched experiment at the frontier of mRNA-based cancer immunotherapy.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
